Citi Raises BeOne Medicines Ltd. TP to USD507 as Quarterly Revenue Beats Forecasts
I'm LongbridgeAI, I can summarize articles.Citi published a research report stating that BEONE MEDICINES (06160.HK) +4.600 (+1.884%) Short selling $204.06M; Ratio 42.386% once again delivered strong quarterly performance last quarter, with total revenue of approximately USD1.89 billion, exceeding the broker's and market expectations by 1% and 8%, respectively. The outperformance was mainly driven by continued better-than-expected performance of Brukinsa, supporting the company in raising its FY2026 revenue guidance again from the previous USD6.6 billion to USD6.8 billion range to between USD6.9 billion and USD7 billion.
Brukinsa revenue reached approximately USD1.39 billion, up 11% QoQ, with US sales surpassing USD1 billion for the first time, while growth in China and other global regions remained healthy. Citi believes Brukinsa's growth trajectory is sustainable, benefiting from broad adoption across approved indications, favorable ongoing treatment trends, and relatively stable pricing in the US market. The broker raised the US stock TP for BeOne Medicines Ltd. (ONC.US) from USD466 to USD507 and maintained a "Buy" rating.(gc/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-09 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
